Effects of dim-evening lighting optimised for geographical orientation versus standard lighting on mental health: protocol paper for a quasiexperimental study in a psychiatric hospital.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
10 Oct 2024
Historique:
medline: 11 10 2024
pubmed: 11 10 2024
entrez: 10 10 2024
Statut: epublish

Résumé

Research has provided novel insights into how light stimulates circadian rhythms through specialised retinal ganglion cells to the suprachiasmatic nucleus. In addition, there has been a revolution in light-emitting diode (LED) technology, leading to tunable LED light sources and lighting systems, enabling 24-hour dynamic light scenarios with bright blue-enriched short wavelength light during the day and dim evening light, stimulating the circadian system. These dynamic LED lighting systems are now being implemented at hospitals without adequate understanding of how it may affect the health and well-being of patients and staff. An optimised dynamic LED lighting scenario is investigated at a newly built psychiatric hospital in Copenhagen. In the 12 months baseline period, a standard lighting scenario with dynamic colour temperature and fixed light intensity is investigated. In the following 12-month intervention period, a new DEL scenario is investigated, having dynamic colour temperature as well as dynamic light intensity with a higher daytime and lower evening-time melanopic daylight equivalent illuminance. This setting is furthermore adjusted for geographical orientation to compensate for differences in sunlight access in wintertime. The study uses a quasiexperimental design comparing patients admitted in the two study periods. Prior to each of the study periods, daylight and the contribution from the LED-lighting scenarios was measured. Patient sociodemographic and mental health data will be retrieved retrospectively from electronic medical records and by questionnaires administered in the two periods, evaluating lighting, noise, sleep quality and quality of life. Primary outcome is the proportion of patients receiving pro re nata medications. Secondary outcomes are the length of stay, sleep onset latency, sleep quality and quality of life. No ethical issues are expected. The results will be disseminated through peer-reviewed international journal, lectures, posters and interviews. NCT05868291.

Identifiants

pubmed: 39389598
pii: bmjopen-2024-086658
doi: 10.1136/bmjopen-2024-086658
doi:

Banques de données

ClinicalTrials.gov
['NCT05868291']

Types de publication

Journal Article Clinical Trial Protocol

Langues

eng

Sous-ensembles de citation

IM

Pagination

e086658

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Carlo Volf (C)

Mental Health Centre Copenhagen, Mental Health Services of the Capital Region of Denmark, Copenhagen, Denmark.

Dennis Dan Corell (DD)

Department of Photonics Engineering, Technical University of Denmark, Lyngby, Denmark.

Torben Skov Hansen (TS)

Chromaviso A/S, Århus, Denmark.

Julie Margrethe Dubois (JM)

Mental Health Centre Copenhagen, Mental Health Services of the Capital Region of Denmark, Copenhagen, Denmark.

Xinxi Zeng (X)

Department of Photonics Engineering, Technical University of Denmark, Lyngby, Denmark.

Lone Baandrup (L)

Mental Health Centre Copenhagen, Mental Health Services of the Capital Region of Denmark and Department of Clinical Medicine University of Copenhagen, Copenhagen, Denmark.

Paul Michael Petersen (PM)

Department of Photonics Engineering, Technical University of Denmark, Lyngby, Denmark.

Klaus Martiny (K)

Mental Health Centre Copenhagen, Mental Health Services of the Capital Region of Denmark and Department of Clinical Medicine University of Copenhagen, Copenhagen, Denmark klaus.martiny@regionh.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH